JP2021527045A5 - - Google Patents
Info
- Publication number
- JP2021527045A5 JP2021527045A5 JP2020567799A JP2020567799A JP2021527045A5 JP 2021527045 A5 JP2021527045 A5 JP 2021527045A5 JP 2020567799 A JP2020567799 A JP 2020567799A JP 2020567799 A JP2020567799 A JP 2020567799A JP 2021527045 A5 JP2021527045 A5 JP 2021527045A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- ethoxy
- hydroxyethyl
- pyridine
- phenyl
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382398.8 | 2018-06-06 | ||
| EP18382398 | 2018-06-06 | ||
| PCT/IB2019/054743 WO2019234689A1 (en) | 2018-06-06 | 2019-06-06 | Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021527045A JP2021527045A (ja) | 2021-10-11 |
| JP2021527045A5 true JP2021527045A5 (https=) | 2022-06-14 |
| JPWO2019234689A5 JPWO2019234689A5 (https=) | 2022-06-14 |
| JP7549344B2 JP7549344B2 (ja) | 2024-09-11 |
Family
ID=62716009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567799A Active JP7549344B2 (ja) | 2018-06-06 | 2019-06-06 | 治療有効量の５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオンを投与する方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210308113A1 (https=) |
| EP (1) | EP3801516A1 (https=) |
| JP (1) | JP7549344B2 (https=) |
| KR (1) | KR20210031435A (https=) |
| CN (1) | CN112512524A (https=) |
| AU (1) | AU2019283649A1 (https=) |
| BR (1) | BR112020024917A2 (https=) |
| CA (1) | CA3102407A1 (https=) |
| CL (1) | CL2020003162A1 (https=) |
| EA (1) | EA202092953A1 (https=) |
| IL (1) | IL279183A (https=) |
| MX (1) | MX2020013181A (https=) |
| SG (1) | SG11202012045UA (https=) |
| WO (1) | WO2019234689A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| FI3801515T3 (fi) | 2018-06-06 | 2025-05-27 | Minoryx Therapeutics S L | 5-[[4-[2-[5-(1-hydroksietyyli)pyridin-2-yyli]etoksi]fenyyli]metyyli]-1,3-tiatsolidiini-2,4-dionia ja sen suoloja käytettäviksi mitokondriosairauksien hoidossa |
| EP4642456A1 (en) | 2022-12-28 | 2025-11-05 | Minoryx Therapeutics S.L. | Optimized dosing of leriglitazone |
| MX2025013233A (es) | 2023-05-09 | 2026-02-03 | Minoryx Therapeutics S L | Formas polimorficas y formulaciones de leriglitazona |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3703058A1 (en) * | 2005-11-29 | 2020-09-02 | Children's Hospital Medical Center | A method of selecting a medication for a patient |
| US20140114676A1 (en) * | 2012-10-23 | 2014-04-24 | Theranos, Inc. | Drug Monitoring and Regulation Systems and Methods |
| EP3125888B1 (en) * | 2014-04-02 | 2018-05-23 | Minoryx Therapeutics S.L. | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders |
| EP3559010B1 (en) | 2016-12-23 | 2022-06-08 | Minoryx Therapeutics S.L. | Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof |
-
2019
- 2019-06-06 BR BR112020024917-3A patent/BR112020024917A2/pt not_active Application Discontinuation
- 2019-06-06 MX MX2020013181A patent/MX2020013181A/es unknown
- 2019-06-06 AU AU2019283649A patent/AU2019283649A1/en not_active Abandoned
- 2019-06-06 EA EA202092953A patent/EA202092953A1/ru unknown
- 2019-06-06 WO PCT/IB2019/054743 patent/WO2019234689A1/en not_active Ceased
- 2019-06-06 JP JP2020567799A patent/JP7549344B2/ja active Active
- 2019-06-06 CA CA3102407A patent/CA3102407A1/en active Pending
- 2019-06-06 SG SG11202012045UA patent/SG11202012045UA/en unknown
- 2019-06-06 US US16/972,368 patent/US20210308113A1/en active Pending
- 2019-06-06 CN CN201980046617.8A patent/CN112512524A/zh active Pending
- 2019-06-06 KR KR1020207037943A patent/KR20210031435A/ko not_active Abandoned
- 2019-06-06 EP EP19742912.9A patent/EP3801516A1/en active Pending
-
2020
- 2020-12-03 IL IL279183A patent/IL279183A/en unknown
- 2020-12-04 CL CL2020003162A patent/CL2020003162A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021527045A5 (https=) | ||
| JP2021527061A5 (https=) | ||
| JP6946477B2 (ja) | アミノアルキルベンゾチアゼピン誘導体の用途 | |
| JP2021169519A5 (https=) | ||
| US9540341B2 (en) | Crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione | |
| JP7510170B2 (ja) | ５－［［４－［２－［５－アセチルピリジン－２－イル］エトキシ］ベンジル］－１，３－チアゾリジン－２，４－ジオンおよびその塩の使用 | |
| EP4309738A2 (en) | Method of treating medulloblastoma with an ezh2 inhibitor | |
| JP2019533642A5 (https=) | ||
| JP7549344B2 (ja) | 治療有効量の５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオンを投与する方法 | |
| US12102644B2 (en) | Compounds and methods of promoting myelination | |
| US20180305396A1 (en) | Deuterated compounds | |
| JP2015500294A (ja) | 金属過剰症を治療する経口製剤 | |
| JPWO2019234689A5 (https=) | ||
| JPWO2019234690A5 (https=) | ||
| JP2021527049A (ja) | ミトコンドリア性疾患の処置における使用のための５−［［４−［２−［５−（１−ヒドロキシエチル）ピリジン−２−イル］エトキシ］フェニル］メチル］−１，３−チアゾリジン−２，４−ジオンおよびその塩 | |
| JPWO2020014504A5 (https=) | ||
| JPWO2023147312A5 (https=) | ||
| AU2019238950B2 (en) | Compounds for treating CNS- and neurodegenerative diseases | |
| EP4470608A1 (en) | Lysophosphatidylserine analogue, and lysophosphatidylserine analogue-containing phamaceutical composition for treating or preventing fibrosis | |
| HK40042762A (en) | Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts | |
| EA047194B1 (ru) | Применение 5-[4-[2-[5-ацетилпиридин-2-ил]этокси]бензил]-1,3-тиазолидин-2,4-диона и его солей | |
| HK40049546A (en) | Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione | |
| WO2024245371A1 (zh) | 一种组合产品、盐及其用于治疗神经退行性疾病或病症的用途 | |
| WO2024245370A1 (zh) | 一种组合产品、盐及其用途 | |
| EA047277B1 (ru) | Способ введения терапевтически эффективного количества 5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-диона |